Sagent Makes Leadership Changes

From DCAT Value Chain Insights (VCI)

By People On The Move posted 03-31-2015 08:51

The Board of Directors of Sagent Pharmaceuticals, Inc. a specialty pharmaceutical products with a specific emphasis on the injectable market, reports that Jeffrey Yordon, chairman and chief executive officer, will retire from the company. He will remain a member of the board. Frank Kung, PhD, a well-regarded industry executive and a member of Sagent's board since 2006, has been named chairman. The board will immediately begin the search for a new CEO. In the interim, the board has formed an Executive Management Committee to lead the company.

Dr. Kung has served as a member of Sagent's Board of Directors since May 2006.He is a founding member of Vivo Capital, LLC and has been the managing partner since February 1997. Prior to that, He held the positions of co-founder, Chairman and Chief Executive Officer of Genelabs Technologies, Inc. and co-founder of Cetus Immune Corporation (later acquired by its parent company, Cetus Corporation). He has served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was also appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. 

Source: Sagent Pharmaceuticals


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription